Related Experiment Video
Updated: Jun 3, 2026
Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
Published on: February 23, 2014
Causative pathogen dictates optimal duration of antimicrobial therapy for ventilator-associated pneumonia in trauma
Louis J Magnotti1, Martin A Croce, Ben L Zarzaur
1Department of Surgery, University of Tennessee Health Science Center, Memphis, TN 38163, USA. lmagnott@utmem.edu
Background:
Recent ventilator-associated pneumonia (VAP) guidelines recommend considering abbreviated therapy in patients with non-Pseudomonas aeruginosa VAP if clinical signs resolve. However, using an arbitrary day cutoff or clinical signs can be suboptimal for some, especially multiply injured patients, resulting in relapse and/or antibiotic resistance. Previously, we showed that repeat bronchoalveolar lavage (BAL) could guide antimicrobial duration for community-acquired VAP in trauma patients. The purpose of this study was to determine the appropriate duration of antimicrobial therapy for VAP in trauma patients secondary to hospital-acquired pathogens.
Study Design:
Patients with VAP secondary to MRSA, Pseudomonas aeruginosa (PA), Acinetobacter baumannii (AB), Stenotrophomonas maltophilia (SM), or Enterobacteriaceae (ENB) during 6 years were evaluated. All received empiric antimicrobial therapy based on duration of ICU stay. Therapy was tailored based on culture data. Repeat BAL was performed on day 4 of appropriate therapy. Microbiological resolution was defined as ≤10(3) colony-forming units/mL. Recurrence was defined as ≥10(5) colony-forming units/mL on subsequent BAL performed within 2 weeks after completion of appropriate therapy.
Results:
Six hundred and fifty-nine patients were identified. Seventy-seven percent of patients underwent repeat BAL: 96 with MRSA, 100 with AB, 139 with PA, 50 with SM, and 120 with ENB. The majority of patients with MRSA or PA achieved microbiological resolution after 14 days. Nearly 60% of patients with AB, SM, or ENB achieved microbiological resolution after 10 days. Overall recurrence was 2%.
Conclusions:
Repeat BAL provides objective evidence for VAP resolution in the face of potentially confounding clinical factors. Hospital-acquired VAP can be managed effectively by a defined course of therapy with a low recurrence. Duration of antimicrobial therapy for VAP in trauma patients should be dictated by the causative pathogen.
Insights
Tailoring antimicrobial therapy duration for ventilator-associated pneumonia (VAP) in trauma patients based on causative pathogens and repeat BAL results can effectively manage VAP and reduce recurrence.
Area of Science:
- Infectious Diseases
- Critical Care Medicine
- Trauma Surgery
Background:
- Current ventilator-associated pneumonia (VAP) guidelines suggest abbreviated therapy for non-Pseudomonas aeruginosa VAP based on clinical signs.
- Arbitrary treatment durations or clinical assessments may be insufficient for multiply injured patients, potentially leading to relapse or antibiotic resistance.
- Previous research indicated repeat bronchoalveolar lavage (BAL) can guide VAP antimicrobial duration in trauma patients with community-acquired pathogens.
Purpose of the Study:
- To determine the optimal duration of antimicrobial therapy for hospital-acquired VAP in trauma patients.
- To evaluate the role of repeat BAL in guiding VAP treatment for hospital-acquired pathogens.
Main Methods:
- Retrospective evaluation of 659 trauma patients with VAP caused by MRSA, Pseudomonas aeruginosa (PA), Acinetobacter baumannii (AB), Stenotrophomonas maltophilia (SM), or Enterobacteriaceae (ENB) over six years.
- Patients received empiric antimicrobial therapy, tailored by culture data, with repeat BAL performed on day 4 of appropriate therapy.
- Microbiological resolution defined as ≤10^3 CFU/mL; recurrence as ≥10^5 CFU/mL on BAL within two weeks post-therapy.
Main Results:
- Repeat BAL was performed on 77% of patients (96 MRSA, 100 AB, 139 PA, 50 SM, 120 ENB).
- Most MRSA and PA VAP cases resolved microbiologically after 14 days of therapy.
- Approximately 60% of AB, SM, and ENB VAP cases achieved resolution after 10 days, with an overall recurrence rate of 2%.
Conclusions:
- Repeat BAL offers objective VAP resolution assessment, overcoming limitations of clinical signs alone.
- Hospital-acquired VAP in trauma patients can be effectively managed with pathogen-directed therapy durations and low recurrence rates.
- Antimicrobial therapy duration for VAP in trauma patients should be guided by the specific causative pathogen.
Related Concept Videos
01:30Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
01:29Pneumonia I: Introduction
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:29Pneumonia II: Pathophysiology
01:30Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
01:14Atypical Pneumonia